Cochlear implantation is a viable treatment for pat ients with severe to profound hearing loss. We report the results of speech perception tests (numb ers, monosyllables, and sentence tests) achieved with MED-EL 's COMBI40+ (C40+) cochlear implant after 12 months of use. These findings, which were taken from a larger German study, were similar to those of other studies of the C40+ implant. We also compared the differenc es in speech perception observed with the CIS PRO+ bodyworn speech processor and the newer TEMPO+ behindthe-ear speech pro cessor. Although these results were similar with respect to most ofthe measured parameters, the TEMPO+ proc essor had a distinct advanta ge during tests in noise.
The C40+ has been investigated in studies in many countries, and speech perception results have been promising. For example, a study of three cases in Russi a revealed that C40+ users experienced appreciable progre ss in hearing during speech discrimination tasks, as well as an improvement in speech production. '?A study in Vienna demonstrated that C40+ users were experiencing a continuous improvement in speech perception 3 years following implantation." The same Viennese team also compared speech perception scores in noise among C40+ user s with those achieved by a similar group of hearing aid user s and found that the implant users recorded higher scores. I I In that study, all C40+ users obtained substantial benefit from their implants in noise, even at a signal-tonoise ratio of 15 dB.
The afor ementioned studies were conducted on patients who used the body-worn CIS PRO+ speech processor. In 1998, MED-EL introduced a new speech processor: the TEMPO+ (figure I). This was the firm's first earlevel speech proce ssor capable of using high-rate stimulation (18, 180 pulses/sec), continuous interleaved sampling (CIS+), and the Hilbert transformation for envelope extraction. The TEMPO+ processor also allows for an upward exten sion of the analyzed frequency range (200 to 10,000 HZ),1 2 which has been shown to improve consonant understanding in quiet." :" The function of the Hilbert transformation is to improve sound quality by allowing for a more accurate determination of the signal envelope providing loudnes s-o ver-time and pitch informarion." :" Initial studies showed that patients who used the TEMPO+ had significantly higher Freiburger monosyllable word score s than did those who used the CIS PRO+. 12 TEMPO+ users also reported a significantly greater improvement in telephone use over time, sound quality, and their ability to enjoy music. In a subjective questionnaire, the vast majority of patients reported that speech understanding with the TEMPO+ was equal to or
Results
Preop eratively , all patients underwent a baseline assessment of their hearing, and all were then ass igned a baselin e score of O. After 12 month s, result s were tabulated for all C40+ users as a group (table) . Furth erm ore, results were also classi fied according to the type of speech proce ssor each patient used . Overall , there appea red to be little differenc e in test scores between the two speechprocessor gro ups, although there did appear to be some adva ntage in favor of the TEMPO+ durin g tests in noise ( figure 2 ). Even at a very difficult signal-to-noise ratio of 0 dB , the TEMPO+ users scored 6.8% higher than did the CIS PRO+ users.
Discussion
In earlier 12-month studies of the C40 (the predecessor of the C40+) , mean speech understanding (monosyllables) scores in quiet ranged from 40 .7 to 54.5 %.5.1 8Our analysis found that the mean percentage of cor rect answers among patients who used the C40+ for 12 months was slightly higher at 58.0% (table) . Likewi se, the mean sentence reco gniti on score in silence see med to be slightly higher among C40+ users (94. 9%) than among C40 user s (89.0%),5 but a definitive conclusion cannot be drawn bec ause the data available for this comparison were too limited. In anoth er study comp arin g the C40+ with the C40 (an extensive data analysis invol ving more than 120 patients), no essential difference in speech recognition in quiet was noted betw een the two groups." Nevertheless, the C40+ has two unequivocal advantages over the C40 . Th e C40+ has more channels (12 vs 8), which allows for gre ater fle xibility in programm ing. It also has a thinner cerami c cas e, which makes it far more suitable for youn g and very young children.
Cochlear implant
All C40+ users better than that experienced with CIS PRO+ , and they rated the sound quality of the TEMPO+ as highe r.
In this article, we report the results of a study of the C40+ impl ant. We al so compar e initial re sults amon g those patient s who switched from using the CIS PRO+ to the TEMPO+ speech processor. OominantLethalTest(Mice) Long-term carcinogenicitystudies in mi ceand rat s have beencom pleted lor ciprofloxacin. After dailyoral doses of 750 mglkg (mi ce) and 250 mglkg(rats) wereadministered for upto 2 years, there was no evidencethat ci profloxacin hadanycarcinogenicortumori genic efleets in thesespecies. No long termstudies ofCIPRO' HCOTIC suspension have been pertormedto evaluate carcinogenicpotent ial. Fertility studies pertormed in rats at oral doses 01 ciprolloxacin up to 100 mglkglday revealed no evidence of impai rment. This would beover 1000 times themaximum recommended cli nical dose 01 ototopical cipr ofloxacinbaseduponbody surtace area, assumingtotal absorption of ci prof loxacinfromthe ear 01apatient treated withCIPRO' HCOTICtwice per day. Long term studies have not been pertorme d to evaluate the carcinogenic potential or Ihe effect on fertility01topical hydrocorti sone. Mutagenicitystudies with hydrocorti sonewerenegative. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproductionsludies have been pertormedin rats and mice usi ng oral doses 01 up to 100 mglkgand IV doses upto 30mglkg and have revealednoevidence of harm to thefetusasa resultof ci prolloxacin. In rabbits, ciprofloxacin (30and 100 mglkgorally) producedgaslrointestinal dist urbances resultingin mat ernalweight loss and an increased incidence01abortion,but noteratogenicitywas observed at eit her dose. After intraven ousadmi nislra tion 01 doses upto20mglkg, no maternaltoxicitywas producedintherabbit, and noembryotoxicityorter atogenicity was observed. Corticosteroids are generally teratogenic in laboralory ani mal s when administered systemica lly at rel atively low dosage level s. The more potent corticosteroids have been show n to beteratogenic after dermalapplicaton in laboratoryanimals. Animal reproduction studieshave not been conducted with CIPRO' HC OTIC. No adequate and well controlled studies have been pertormed in pregnant women. Caution should be exerci sed when CI PRO' HCOTICis used by a pregnanl woman. Nursing Mothers: Ciprolloxacin is excreted in humanmilk with systemic use. It is not known whether ciprolloxacin is excreted in humanmilkloll owingtopi cal oticadmi nistration. Because ofthe potent iallor serious adverse react ionsinnursinginfants, adecision shouldbemade whethertodiscontinuenursingor to discont inuethedrug, taking intoaccount the importance ofthedrug tothemother . Pediatricuse: The sa letyand efficacy of CIPRO' HC OTIC have beenestablished in pediatric patients 2 years and older (131_patients) in adequate and well-controlled clinical tri als. Although no data are available on patients less thanage2 years, there are no known safety concerns or differences in the disease processinthispopulation whichwould precludeuse of thi s product in patientsone year and older. See OOSAGE ANO AOMINISTRATION. AOVERSE REACTIONS In Phase3 clinical tri als, a totalof 564patient s were treatedwith CIPRO' HCOTIC, Adverse events with at least remote rel ationship to treatment incl uded headache (1.2 %) and pruri tus (0.4%). The foll owing treatment-rel ated adverse events were each reported in a single patient: migrai ne, hypesthesia, paresthesia, fungaldermatitis, coug h, rash, urt icaria,and alopecia. Signal-to-noise ratio Figure 2 . Graph illustrat es the mean HSM sentence scores according to signal-to-noise ratio in the CIS PRO+ and TEMPO+ speech-processor groups .
Our comparison of the CIS PRO+ and TEMPO+ speech processors found that differences were minimal, except in increasingly difficult noise conditions, where the TEMPO+ wa s more effective. However, further data are needed to support these findings because they might have been influenced by the extended frequency range and the Hilbert transformation used in the CIS+ speech coding strategy.
